NCT05647525

Brief Summary

This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 4, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 12, 2022

Completed
Last Updated

December 15, 2022

Status Verified

December 1, 2022

Enrollment Period

1.7 years

First QC Date

December 4, 2022

Last Update Submit

December 13, 2022

Conditions

Status Epilepticus

Outcome Measures

Primary Outcomes (1)

  • Death

    2021-12--2022-12

Study Arms (1)

status epilepticus with autoimmune encephalitis; status epilepticus without autoimmune encephalitis

To study the relationship between autoimmune-related antibody titres and prognosis during the six-month follow-up

Diagnostic Test: Perform autoimmune encephalitis titer tests

Interventions

Perform autoimmune encephalitis titer testsDIAGNOSTIC_TEST

We only follow up without intervention.

Also known as: We only follow up without intervention.
status epilepticus with autoimmune encephalitis; status epilepticus without autoimmune encephalitis

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients were selected strictly according to the inclusion and exclusion criteria from January 2021 to December 2022 at Sichuan Academy of Medical Sciences. Inpatient NOSE patients at Sichuan Provincial People's Hospital

You may qualify if:

  • Clinical diagnosis of Status Epilepticus
  • Sign the informed consent form

You may not qualify if:

  • Patients with previous epilepsy
  • Missing information such as basic information and treatment history
  • Long-term smoking, alcohol and drug abuse
  • Pregnant and breastfeeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jie Liu

Chengdu, Sichuan, China

Location

MeSH Terms

Conditions

Status Epilepticus

Condition Hierarchy (Ancestors)

SeizuresNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 4, 2022

First Posted

December 12, 2022

Study Start

January 1, 2021

Primary Completion

August 30, 2022

Study Completion

September 30, 2022

Last Updated

December 15, 2022

Record last verified: 2022-12

Locations

CN(1)